Truist sets USD 55.00 target for Alkermes stock

Published on 10/17/2026 at 20:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alkermes earnings are estimated for October 28, 2026. Alkermes stock was USD 41.22 on October 16, 2026, up 2.79 percent versus USD 40.10.

Analyst target and earnings date

Truist resumed coverage with a USD 55.00 target on October 16, 2026.
Alkermes earnings are estimated for October 28, 2026.
Alkermes stock was last at USD 41.22 on October 16, 2026 at 4:00 p.m. ET, up 2.79 percent versus the USD 40.10 prior close.
Alkermes had a trailing P/E ratio of 107.62 as of October 16, 2026.

ALKS, IE00B56GVS15, Illustration mit AI erstellt.

Truist resumed coverage of Alkermes with a Buy rating and a USD 55.00 price target on October 16, 2026, according to GuruFocus. The target is 33.19 percent above the Nasdaq price of USD 41.22. Alkermes was last at USD 41.22 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 2.79 percent versus the USD 40.10 prior close.

Results date sets the next checkpoint

Alkermes is estimated to report third-quarter 2026 results on October 28, 2026, before the market opens. The conference call is scheduled for October 27, 2026 at 8:00 a.m. ET, according to MarketBeat. The estimates cited there call for revenue of USD 463.35 million and adjusted earnings per share of minus USD 0.0788 for the quarter.

Stock sits inside its yearly range

The Nasdaq price stood 26.05 percent below Alkermes' 52-week high of USD 55.67 and 52.67 percent above its low of USD 27.00 on October 16, 2026. Trading volume reached 3,263,631 shares, compared with an average volume of 1,882,673 shares. The move therefore came with volume 73.37 percent above the average.

Valuation and pipeline context

Alkermes had a market capitalization of USD 6.9 billion and a trailing P/E ratio of 107.62 as of October 16, 2026. The company develops medicines for central nervous system disorders, including addiction, schizophrenia, bipolar disorder and narcolepsy, according to its corporate profile. Truist linked its new target to the companys orexin-2 receptor agonist platform.

Comparison with peers

Alkermes (Nasdaq, USD): plus 2.79 percent, P/E 107.62, market capitalization USD 6.9 billion.
AbbVie (NYSE, USD): plus 0.71 percent, P/E 80.42, market capitalization USD 504.4 billion.
Bristol-Myers Squibb (NYSE, USD): minus 1.35 percent, P/E 13.16, market capitalization USD 122.1 billion.

Price and dates guide the view

For investors, the immediate contrast is between a USD 55.00 analyst target and a share price of USD 41.22, while the October 28, 2026 reporting date provides the next scheduled test of that valuation. The companys latest investor materials identify second-quarter 2026 results among its reporting periods, while the coming release will provide the next comparable operating update.